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EphB4 is a member of the largest family of transmembrane receptor tyrosine kinases and plays critical roles in axonal pathfinding and
blood vessel maturation. We wanted to determine the biological role of EphB4 in ovarian cancer. We studied the expression of
EphB4 in seven normal ovarian specimens and 85 invasive ovarian carcinomas by immunohistochemistry. EphB4 expression was
largely absent in normal ovarian surface epithelium, but was expressed in 86% of ovarian cancers. EphB4 expression was significantly
associated with advanced stage of disease and the presence of ascites. Overexpression of EphB4 predicted poor survival in both
univariate and multivariate analyses. We also studied the biological significance of EphB4 expression in ovarian tumour cells lines in
vitro and in vivo. All five malignant ovarian tumour cell lines tested expressed higher levels of EphB4 compared with the two benign cell
lines. Treatment of malignant, but not benign, ovarian tumour cell lines with progesterone, but not oestrogen, led to a 90% reduction
in EphB4 levels that was associated with 50% reduction in cell survival. Inhibition of EphB4 expression by specific siRNA or antisense
oligonucleotides significantly inhibited tumour cell viability by inducing apoptosis via activation of caspase-8, and also inhibited tumour
cell invasion and migration. Furthermore, EphB4 antisense significantly inhibited growth of ovarian tumour xenografts and tumour
microvasculature in vivo. Inhibition of EphB4 may hence have prognostic and therapeutic utility in ovarian carcinoma.
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Ovarian cancer is the second most common gynecologic cancer
in women, with an estimated 22220 new cases in the United
States in the year 2005 (American Cancer Society, 2005). Ovarian
cancer causes more deaths than any other cancer of the
female reproductive system. The vast majority of ovarian cancers
is epithelial in origin. Ovarian cancer has a higher incidence in
women who carry BRCA or mismatch repair gene mutations
(Matias-Guiu and Prat, 1998). The role of female sex hormones on
the progression of ovarian cancer has also been studied. It is
believed that certain metabolites of oestrogen may support tumour
growth, whereas progesterone may have a protective role (Seeger
and Mueck, 2006). No effective screening tool exists for ovarian
cancer and in over 80% cases, the diagnosis is not made until the
disease is advanced, making treatment particularly challenging.
The current overall 5-year survival is 44%; however, the relative
5-year survival for women with distant disease is only 29%
(American Cancer Society, 2005). There is hence a need to identify
new molecular markers that play a role in the pathogenesis of
ovarian cancer with a hope to offer novel, targeted, biological
therapy.
Receptor tyrosine kinases are a diverse group of transmembrane
proteins involved in signal transduction pathways that control cell
proliferation, differentiation, and migration. The Eph receptors are
the largest family of tyrosine kinases, comprising of 15 individual
members, divided into EphA and EphB classes. Recently, several
studies have documented high expression of the Eph family of
receptor tyrosine kinases in tumours (Stephenson et al, 2001;
Berclaz et al, 2003; Wu et al, 2004, 2006; Lee et al, 2005; Xia et al,
2005, 2006; Kumar et al, 2006; Masood et al, 2006). Although there
is limited data on the protein levels of EphB4 in cancers, only
recently, data on the biological significance of this protein in
tumour biology is being accrued. Evidence for a potential role as a
tumour promoter comes from EphB4/neuT transgenic mice, which
develop tumours more rapidly than neuT transgenic mice
(Munarini et al, 2002).
EphB4 and its ligand EphrinB2 show complementary expression
on venous and arterial endothelial cells, respectively (Wang et al,
1998), and play a critical role in vessel maturation. Knockout of
either protein is embryonically lethal in mice owing to vascular
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sarrest at the primitive capillary plexus stage (Gerety et al, 1999).
Therefore, overexpression of EphB4 by cancers can likely provide
an angiogenic advantage to them. However, there is growing
evidence that EphB4 may provide more direct survival cues to
cancer cells. We have shown recently such a role of EphB4 in
prostate (Xia et al, 2005), bladder (Xia et al, 2006), breast (Kumar
et al, 2006), and head and neck cancers (Masood et al, 2006). In
this report, we extend those findings to ovarian cancer as well. We
demonstrate a high level of expression of EphB4 in human ovarian
tumours, which correlates with advanced stage and short survival.
Furthermore, all five ovarian carcinoma cell lines express EphB4.
Overexpressed EphB4 provides survival advantage to tumour cells
by inhibiting cell membrane originating (extrinsic) apoptosis, and
affords an invasive phenotype by promoting tumour cell invasion.
EphB4 knockdown effectively reverses these phenomena and
inhibits tumour growth in a murine xenograft model of ovarian
cancer. EphB4 is thus a novel ovarian tumour marker and a viable
target for biological therapy.
MATERIALS AND METHODS
Reagents
EphrinB2 (P20) antibody was purchased from Santa Cruz Biotech
(Santa Cruz, CA, USA). The anti-phospho-tyrosine antibody 4G10
was from Upstate (Lake Placid, NY, USA), monoclonal anti-actin
antibody from Sigma Chemical Co (St Louis, MO, USA), anti-CD31
(M20) from Santa Cruz Biotech (Santa Cruz, CA, USA), mono-
clonal anti-Ki-67 from DAKO (Carpentaria, CA, USA), and anti-
human Fc from Jackson Labs (Bar Harbor, ME, USA). EphrinB2/Fc
chimeric protein was from R&D Systems Inc. (Minneapolis, MN,
USA). All antisense ODNs and siRNAs were synthesised from
Qiagen (Valencia, CA, USA).
Monoclonal antibodies to the extracellular domain of EphB4
were generated in-house at Vasgene Therapeutics (three different
clones designated MAb131, MAb47, and MAb265). These
antibodies have been characterized extensively in-house and are
extremely sensitive and specific for the extracellular domain of
EphB4 receptor. They do not cross react with other members of the
Eph family of receptors (data not shown). MAb265 detects only
denatured human EphB4 on Western blot, MAb131 detects human
EphB4 on tissue sections, whereas MAb47 detects human and
murine EphB4 and is very effective in immunoprecipitation
experiments.
Cell culture
ML5 and ML10 cells were derived from human ovarian
cystadenomas and transfected with SV40 large T antigen to
increase their longevity in vitro. MCV 50 cells were derived from a
subclone of ML10 that became spontaneously immortalized in
culture. HOC-7 ovarian carcinoma cells were obtained from Dr R
Buick (University of Toronto). OVCAR-3 cells were purchased
from ATCC (ATCC#HTB161). ML5, ML10, and MCV50 were
cultured in MEM medium supplemented with 10% FCS, 1mM
glutamine, and 1% penicillin–streptomycin (Invitrogen, Carlsbad,
CA, USA). HOC-7 and OVCAR-3 cells were maintained in RPMI
medium supplemented with 10% FCS, 1mM glutamine, and 1%
penicillin–streptomycin. Hey and CAOV-3 cells were cultured in
DMEM medium containing 10% FCS, 1mM glutamine, 1mM MEM
sodium pyruvate, and 1% penicillin–streptomycin.
EphB4 siRNAs and antisense oligodeoxynucleotides
EphB4-specific siRNA and phosphorothioate-modified antisense
or scrambled oligodeoxynucleotide (ODN) were synthesised
(Qiagen, Valencia, CA, USA) and tested for specific inhibition of
the EphB4 expression. EphB4-specific siRNA corresponded to the
sequence 50-GGU GAA UGU CAA GAC GCU GUU-30 and 30-UUC
CAC UUA CAG UUC UGC GAC-50. The specific siRNA was
mutated at three sites to yield siRNAD,5 0-AGU UAA UAU CAA
GAC GCU GUU-30 and 30-UUU CAA UUA UAG UUC UGC GAC-50,
which had no effect on EphB4 levels and was used as control.
SiRNA directed against GFP was used as an additional negative
control. The AS-ODN used, AS-10, spanned nucleotides 1980–
1999 with a sequence 50-ATG GAG GCC TCG CTC AGA AA-30.T o
negate nonspecific cytokine-mediated effects from the CpG site,
the cytosine in position 11 was methylated (AS-10M) without loss
in EphB4 knockdown effect (data not shown). Scrambled ODN
(sequence 50-AAG GGC TAG GAT AGA CCC TC-30) with the same
nucleotides in a random sequence containing a CpG site as well
was used as control.
Immunohistochemistry
All of the human samples were collected in compliance with
requirements of the Institutional Review Board for the Protection
of Human Subjects. Formalin-fixed, paraffin-embedded samples
were sectioned at 5mm. Sections were treated with antigen retrieval
buffer (modified citrate buffer with DIVA decloaker, BioCare
Medical, Concord, CA, USA). Specifically primary monoclonal
EphB4 antibody MAb131 was applied overnight at room tempera-
ture at a concentration of 30mgml
 1 in 1% BSA/TBST. Slides were
incubated in secondary antibody. Immunostaining was carried out
using standard techniques (details available on request).
All of the samples were reviewed by a board-certified pathologist
who was blinded to clinical outcome of the patients. EphB4
expression was determined by assessing the percentage of stained
tumour cells and staining intensity. The percentage of positive cells
was scored as follows: 0 points, 0–5%; 2 points, 6–50%; 3 points,
450%. The staining intensity was scored as follows: 1 point, weak
intensity; 2 points, moderate intensity; 3 points, strong intensity.
Points for expression and percentage of positive cells were added
and an overall score between 0 and 6 was assigned. Tumours were
categorized into four groups: negative (overall score¼0); weak
expression (overall score¼1–2); moderate expression (overall
score¼3–4); and strong expression (overall score¼5–6). For
xenograft staining, sections were incubated with primary antibody
(CD31 1:250 dilution, Ki-67 1:100 dilution) overnight at 41C.
Routine negative controls included deletion of primary and
secondary antibody and substitution of normal IgG isotope for
primary antibody. When using mouse-anti-human Ki-67 antibody,
MOM kit (Vector Labs, Burlingame, CA, USA) was used to block
nonspecific binding to mouse tissue. Number of cells staining
positive was counted by a blinded observer in five random high-
power fields.
Western blot
Cell lysates were prepared as described by Masood et al, (2003).
Typically, 10mg proteins from whole-cell lysate were fractionated
on a 4–20% Tris–glycine polyacrylamide gel, electro-transferred
to PVDF membrane, and probed with primary antibody overnight.
Blot was stripped with Restoret Western blot stripping buffer
(Pierce, Rockford, IL, USA) and reprobed with b-actin to confirm
equivalent loading and transfer of protein. Signal was detected
using SuperSignal West Femto Maximum Sensitivity Substrate
(Pierce), quantitated by X-ray densitometry using Fluro-S multi-
Imager system (Bio-Rad).
Phosphorylation analysis of EphB4
Recombinant EphrinB2/Fc or Fc proteins were clustered using
anti-Fc antibody for 1h at 41C. Hey and Hoc-7 cells were grown
in 60mm dishes until 100% confluence and were treated with
clustered EphrinB2/Fc or Fc (Jackson Labs) for various durations
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sof time. Lysates were prepared with buffer containing 20mM Tris–
HCl, pH 8.0, 150mM NaCl, 1% (v/v) Triton-X100, 1mM EDTA,
1m M PMSF, 1mM sodium vanadate, and centrifuged at 50000g for
60min at 41C. Clarified protein samples were incubated overnight
with protein A/G coupled agarose beads pre-coated with anti-
EphB4 monoclonal antibody (#47). The immunoprecipitated
complexes were probed with anti-p-Tyr-specific antibody 4G10.
EphB4 precipitation efficiency was tested by probing with EphB4
specific monoclonal antibody (#265).
Wound-healing migration assay
Hey cells were seeded onto six-well plates and cultured until
confluent. EphB4 antisense or scrambled ODN (1mM) or siRNA
were introduced to the wells as described for the viability assay.
Cell monolayer was wounded by scraping with a sterile pipette tip.
Migration of the cells into scraped area over time was examined
and recorded with a Nikon Coolpix 5000 digital camera.
Cell migration assay
Chemotaxis of ovarian cells was assessed using a modified Boyden
chamber containing cell culture inserts with an 8mm pore
size Matrigel-coated polycarbonate membrane in 24-well plates
(BD Biosciences). The cell suspensions of Hey (2 10
5cellsml
 1)
in 200ml DMEM/1%FCS were seeded in the upper chamber
following siRNA introduction or along with EphB4 AS-10. Five
hundred microlitres of DMEM/1%FCS containing chemotaxis
agent EGF (20ngml
 1) was added to the lower chamber. After
incubation for 9h at 371C, the upper surface of the filter was
scraped with swab and filters were fixed and stained with Diff
Quick (vWR, West Chester, PA, USA).
Cell viability assay
Hey and Hoc-7 cells were seeded on 48-well plates at a density of
approximately 1 10
4cellswell
 1 in 200ml medium. Cells were
treated with various concentrations (1–10mM) of EphB4 AS-10
or scrambled ODN on day 1 and day 3 after cell seeding. After
3 days, medium was changed and fresh ODNs added. Cell via-
bility was assessed by MTT as described previously (Masood
et al, 2003). EphB4 siRNAs (10–100nM) were introduced into
2 10
4cellswell
 1 of a 48-well plate using 2ml of Lipofectaminet
2000 according to the manufacturer’s instructions. Four-hour
post-transfection, the cells were returned to growth medium.
Viability was assayed after 48h as described by Masood et al
(2003).
Cell-cycle analysis
Eighty per cent confluent cultures of Hey cells in six-well plates
were transfected with various siRNAs (100nM) using Lipofectami-
net 2000 for variable amount of time, cells were trypsinized,
washed in PBS, and incubated for 1h at 41C in 1ml of hypotonic
solution containing 50mgml
 1 propidium iodide, 0.1% sodium
citrate, 0.1 Triton X-100, and 20mgml
 1 DNase-free RNaseA. Cells
were analysed in linear mode by flow cytometry. Results are
expressed as percentages of elements detected in the different
phases of the cell cycle, namely sub-G0 peak (apoptosis), G0/G1 (no
DNA synthesis), S (active DNA synthesis), G2 (premitosis) and M
(mitosis).
Apoptosis assay
Apoptosis was studied using the Cell Death Detection ELISA
plus Kit that detects cytoplasmic nucleosomes according to the
manufacturer’s instructions (Roche, Piscataway, NJ, USA). Briefly,
cell in 24-well plates cultured to 80% confluence were transfected
using Lipofectaminet 2000 with various concentrations (0–
100nM) of EphB4 siRNA(472) or GFP siRNA. After 16h, cells
were lysed and nuclei pelleted, incubated with anti-histone-biotin
and anti-DNA POD in streptavidin-coated 96-well plate. Colour
was developed with ABST and absorbance at 405nm was read
in a microplate reader (Molecular Devices, Sunnyvale, CA, USA).
Caspase-8 and -9 activity was measured using the caspase-8 and
caspase-9 colorimetric assay kits that monitor cleavage of caspase-
8 and -9 peptide substrates (R&D Systems Inc., Minneapolis, MN,
USA). Apoptosis was detected in deparafinised sections of animal
tumours by TUNEL assay using the in situ cell-death detection kit
(Roche, Piscataway, NJ, USA) according to the manufacturer’s
instructions.
Murine tumour xenograft model
Hey cells were propagated, collected by trypsin digestion, and
re-suspended in serum-free medium. 2 10
6 cells were injected in the
flank of 10- to 12-week-old female Balb/C athymic mice. Tumour
growth was measured three times a week and volume estimated as
0.52 a b
2, where a and b are the largest and smallest lengths of
the palpable tumour. On day 4 after cell implantation, tumour
volumes were calculated to ensure uniformity in size and animals
were divided randomly into three groups (n¼6 mice per group).
Each group was administered daily by intraperitoneal injec-
tion, AS-10 or scrambled ODN at a dose of 10mgkg
 1 or vehicle
alone (sterile normal saline, pH 7.4). Animals were killed and
tumours and normal organs harvested after 4 weeks. A portion of
the tumours was fixed in formalin for paraffin-embedding and
histologic analysis. The remaining tumour tissue and organs in
each group were pooled and protein was extracted. All procedures
were approved by our Institutional Animal Care and Use
Committee and performed in accordance with the Animal Welfare
Act regulations.
Statistical analysis
The w
2 test was used to determine differences among variables
using SPSS (SPSS Inc., Chicago, IL, USA). Survival curves were
generated with the Kaplan–Meier method and compared with
the log-rank statistic. The Cox proportional hazards model was
used for multivariate analysis. Student’s t-test was used to compare
tumour volumes. A Po0.05 was considered statistically significant.
RESULTS
EphB4 expression in human ovarian tumour samples
EphB4 expression in human ovarian samples was assessed
by immunohistochemical staining of sections isolated from seven
normal ovaries and 85 invasive epithelial ovarian cancers
(Figure 1A). All of the normal ovaries had little or absent EphB4
expression on the surface epithelium (Figure 1Ab). Among the
invasive ovarian cancers, 73 (86%) expressed EphB4 and moderate
or strong expression was noted in 49 (58%) samples. We
confirmed EphB4 expression by Western blot in a select group
of 10 ovarian tumour samples for which frozen tissues were
available. Seven of 10 tumour specimens expressed EphB4 on
Western blotting (data not shown), confirming the staining data.
EphB4 expression correlates with clinicopathological
features
The demographic features of patients with invasive ovarian cancer
are summarised in Figure 1B. Mean age at presentation was 59.4
(range¼34–86) years. Sixty-nine of 85 patients (81%) had
advanced stage (III or IV) disease, and 74 of 85 patients (87%)
had high-grade (II or III) disease. Fifty-six out of 85 patients (66%)
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sunderwent optimal surgical cytoreduction (o1cm residual disease
at completion of surgery). There was no association between
expression of EphB4 and histological subtype, tumour grade or
extent of cytoreduction.
EphB4 overexpression correlated with advanced disease stage.
High expression of EphB4 was detected in 69% of high-stage
ovarian cancers compared with 19% of low-stage ovarian cancer
(Po0.001). Ninety per cent of patients with EphB4 overexpression
had ascites compared with 49% of patients without EphB4 over-
expression (Po0.001). Survival rates of patients with invasive
ovarian cancer and EphB4 expression were determined using the
Kaplan–Meier method (Figure 1C). In univariate analysis, EphB4
overexpression was associated with significantly worse survival
compared with low expression (median survival¼7.75 years vs
2.58 years; Po0.001). On multiple regression analyses using a Cox
proportional hazards model that included EphB4 expression, stage,
grade, ascites, histology, and level of cytoreduction, only advanced
stage (P¼0.04), EphB4 overexpression (P¼0.003), and sub-
optimal cytoreduction (P¼0.017) were significant predictors of
poor survival.
EphB4 receptor is highly expressed in ovarian carcinoma
cell lines
To study the biological role of EphB4, we wanted to determine
the expression level of EphB4 in ovarian carcinoma cell lines
in comparison with benign ovarian tumour cell lines. Western
blots revealed that EphB4 was indeed expressed highly in ovarian
carcinoma cell lines Hey, CAOV-3, Hoc-7, and OVCAR-3, and least
in the benign ovarian cell lines MCV-50 and ML-5 (Figure 2A).
Hoc-7 expressed high levels of EphB4 compared with other ovarian
cell lines. EphrinB2 is expressed at negligible level to low levels in
all ovarian cell lines, including the benign ovarian cell line (ML-5).
An equal amount of protein loaded in each lane was confirmed by
probing the same blots for b-actin (Figure 2A). EphB4 expressed
on ovarian cancer cell lines is functional. Stimulation of Hey cells
with 3mgml
 1 EphrinB2/Fc chimeric protein (in the absence of
serum), but not Fc fragment alone, results in phosphorylation of
EphB4 in 10min, which begins to diminish by 60min (Figure 2B).
Also, addition of foetal calf serum to serum-starved Hey cells
induces a small degree of EphB4 phosphorylation above baseline.
Progesterone reduces EphB4 expression and cell growth
Menstrual hormones are known to regulate ovarian tumour
development and progression (Danforth et al, 2007). In particular,
progesterone is growth inhibitory in several previous reports
(Seeger and Mueck, 2006). We were therefore interested in
determining if progesterone and oestrogen affect the expression
of EphB4. Hoc-7 cells express functional progesterone and
oestrogen receptor. Treatment of Hoc-7 cells with progesterone
led to a dose-dependent reduction in EphB4 expression, whereas
oestrogen had no effect on EphB4 levels (Figure 2C). Both
hormones had no effect on EphB4 expression in the benign
MCV-50 cells (Figure 2C and data not shown). Progesterone, but
not oestrogen, similarly inhibited EphB4 expression in Hey cells as
well (data not shown). Both Hoc-7 and Hey cells treated with
progesterone showed a dose-dependent reduction in cell survival.
Ten micromolar progesterone resulted in nearly 50% reduction in
cell survival in Hoc-7 cells (Figure 2D).
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Figure 1 EphB4 is expressed in human ovarian tumour specimens and correlates with advanced stage, presence of ascites, and poor survival. (A)
Representative immunohistochemical peroxidase staining for EphB4 in a negative (deletion of primary antibody) control (a), normal ovarian epithelium (b),
and invasive ovarian carcinoma (c). All pictures were taken at original magnification of  200. (B) Correlation of clinical and pathological variables with
EphB4 overexpression in ovarian carcinoma. (C) Kaplan–Meier survival of patients with invasive ovarian cancer based on EphB4 staining intensity, using the
log-rank statistic.
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sInhibition of EphB4 results in reduced viability
To determine the biological function of EphB4 in ovarian cancer,
we designed several siRNAs to knockdown EphB4 expression and
selected the compound that best-inhibited EphB4 expression on
Western blots (Figure 3A, upper panel). EphB4 siRNA lead to a
corresponding dose-dependent reduction in EphB4 expression
levels in Hoc-7 cells as well (data not shown). Transfection with
EphB4 siRNA mutated at three bases (EphB4 siRNAD)o r
nonspecific GFP siRNA had no effect on expression levels of
EphB4 (data not shown), indicating that the reduction in EphB4
expression is a specific effect of EphB4 siRNA. Concomitant with
reduction in levels of EphB4 expression, EphB4 siRNA treatment,
but not treatment with mutated EphB4 siRNAD, resulted in a
dose-dependent reduction in Hey cell numbers. At a dose of 25nM
siRNA, nearly 90% cell number was reduced (Figure 3A, lower
panel). The dose of siRNA to achieve 50% cell number reduction
was 4nM. Similarly, treatment of HOC-7 cells with 25nM EphB4
siRNA resulted in 75% reduction in cell numbers (data not shown).
Treatment of EphB4-negative tumour cell lines with EphB4 siRNA
does not affect tumour cell numbers (Xia et al, 2005 and data not
shown).
For use in vivo, we generated a panel of EphB4 antisense oligo-
nulceotides and selected the molecule AS-10 that had maximal
reduction in EphB4 levels for further studies (Figure 3B, upper
panel). Similarly, treatment with 10mM AS-10, but not scrambled
ODN, resulted in 90% reduction in cell numbers, with an ED50 of
4mM (Figure 3B, lower panel).
Knockdown of EphB4 leads to apoptosis and activation of
the death receptor caspase pathway
We were interested in determining the cause for reduced cell
numbers following EphB4 knockdown. Hey cells were transfected
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Figure 2 Ovarian cancer cell lines express functional EphB4 that is downregulated by progesterone. (A)2 0mg total cell lysate from each of the ovarian
cancer cell lines was run on 4–20% Tris-glycine gel and transferred to PVDF membrane. The membrane was sequentially probed with anti-EphB4, anti-
EphrinB2, and anti-b-actin antibody. (B) Hey cells were serum starved overnight and stimulated for the various time periods shown with 3mgml
 1 clustered
EphrinB2/Fc or Fc alone. EphB4 was immunoprecipitated from 100mg whole-cell lysates and phosphorylation status analysed by antiphosphotyrosine
antibody immunoblotting (top row). A duplicate membrane was probed for EphB4 to document immunoprecipitation efficiency (bottom row). (C) Hoc-7
(ovarian cancer) and MCV-50 (ovarian cystadenoma) cells were treated with varying doses of progesterone and oestrogen for 36h and cell lysates were
analysed by immunoblotting for expression of EphB4, EphrinB2, and b-actin. (D)1 10
4 Hoc-7 cells were plated in each well of a 48-well plate and treated
for 72h with varying doses of progesterone and oestrogen. Cell viability was assessed by MTT assay and survival expressed as percentage of absorbance
relative to untreated cells.
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swith 25nM EphB4 siRNA and 36h later, subjected to cell-cycle
analysis (Figure 3C). Although 90% of control cells and 88%
of EphB4 siRNAD transfected cells entered the G0 phase and
progressed along the cell cycle, only 48% of EphB4 siRNA-treated
cells progressed into the cell cycle.
Preventing cells from entering the G0 phase of the cell cycle
is consistent with induction of apoptosis. To further corroborate
this, we quantitated cytoplasmic nucleosomes by ELISA in Hey
cells 48h after transfection with EphB4 siRNA (Figure 3D).
Transfection with 25nM EphB4 siRNA resulted in a three-fold
increase in cytoplasmic nucelosomes, whereas transfection with
EphB4 siRNAD had no effect. Apoptosis can be induced by
activation of the extrinsic, membrane-originating pathway that
involves casapse-8, or the intrinsic mitochondrial pathway that
does not involve casapse-8. Transfection of Hey cells with 25nM
EphB4 siRNA resulted in 3.2-fold activation in caspase-8, whereas
no such effect was observed with EphB4 siRNAD (Figure 3E).
Neither the active nor the mutated siRNA resulted in appreciable
casapse-9 activation. EphB4 antisense oligonucleotides induced a
similar cell-cycle profile and caspase-8 activation (data not
shown). Thus, EphB4 knockdown in Hey cells results in cell death
owing to induction of apoptosis predominantly via the extrinsic
caspase-8 pathway.
EphB4 regulates cell migration and invasion
The higher levels of expression of EphB4 in malignant compared to
benign cell lines could be suggestive of higher EphB4 levels
contributing to more malignant behaviour by increasing cell
migration and invasion of extracellular matrix proteins. We
therefore determined if EphB4 participates in the migration of
ovarian cell lines. These experiments were carried out over much
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Figure 3 EphB4 knockdown leads to tumour cell apoptosis. (A) Hev cells were transiently transfected with EphB4-specific siRNA (EphB4-siRNA) and
48h later, 20mg whole-cell lysates were analysed by immunoblotting for EphB4 and b-actin levels (top panel). 1 10
4 Hey cells were transfected with
mutated EphB4 siRNAD or native EphB4-siRNA and plated in a 48-well plate. Cell viability was assessed by MTT assay at 48h and survival expressed as
percentage of absorbance relative to untreated cells (bottom panel). (B) Hey cells were treated with varying doses of EphB4-specific ODN (AS-10).
Seventy-two hours later, 20mg whole-cell lysates were analysed by immunoblotting for EphB4 and b-actin levels (top panel). 1 10
4 Hey cells were treated
with scrambled or AS-10 ODN. Cell viability was assessed by MTT assay at 72h and survival expressed as percentage of absorbance relative to untreated
cells. (C) Hey cells were transiently transfected with EphB4-specific siRNA (EphB4-siRNA) or mutated siRNA (EphB4-siRNAD). Apoptosis was analysed by
ELISA for cytoplasmic nucleosomes as detailed in the Materials and Methods section using whole-cell lysates. (D) Caspase-8 and caspase-9 activation was
assayed colorimetrically in these cells and expressed as percent activity compared with lipofectamine-treated cells. (E) Cell-cycle analysis of Hey cells treated
with lipofectamine alone (control) or treated with 25nM EphB4-specific siRNA (EphB4 siRNA) or mutant siRNA (EphB4 siRNAD) for 36h. The percentage
of cells in G0,G 1,S ,G 2, and M phase are indicated. Similar results were obtained in three independent experiments.
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sshorter time periods (9–12h), at which times no appreciable cell
death was observed. Confluent Hey cultures were wounded by a
single scrape with a sterile plastic Pasteur pipette, which left a
3mm cell-free zone with clearly defined borders. Migration of cells
into the cleared zone in the presence of EphB4 siRNA and EphB4
AS-10 were evaluated and quantified over 9h. Control cells and
EphB4 siRNAD-transfected cells migrate rapidly to cover the
wound resulting in near complete wound healing by 9h, whereas
transfection of 25nM EphB4 siRNA results in marked inhibition of
cell migration and wound healing at 6 and 9h (Figure 4A). A
similar reduction in cell migration was observed with AS-10 (data
not shown).
Malignant cells are capable of degrading extracellular matrix
and invading through tissues. To study this function, Hey cells
were cultured on Matrigel coated on the inner chamber of a
Boyden double chamber for 12h in the presence of 10mg EGF
in the outer chamber. Cells migrating to the under surface of
the inner chamber were stained and visualised 12h later. Control
cells migrated readily to the under surface of the membrane in
12h (Figure 4B). Whereas transfection with EphB4 siRNAD had
no effect on cellular invasion, EphB4 siRNA nearly completely
abolished cell migration across the basement membrane. A similar
effect was observed with AS-10 (data not shown). Thus, EphB4
confers to ovarian cancer cells the ability to migrate and invade
basement membranes, known characteristics of an aggressive
malignancy.
EphB4 antisense ODN inhibits tumour growth in vivo
We then studied the effect of systemic antisense administration in
mice-bearing human ovarian cancer xenografts. 2 10
6 Hey cells
were injected in the flank of 10- to 12-week old, female Balb/C
athymic mice. On day 4 after cell implantation, mice were divided
randomly into three groups (n¼6 mice per group, experiment
repeated twice) and treated by intraperitoneal injection with
PBS (vehicle), scrambled ODN or AS-10 at a dose of 10mgkg
 1.
Over 5 weeks, AS-10 treatment resulted in greater than 85%
smaller tumours compared with vehicle-treated tumours, whereas
scrambled ODN treatment had no effect (Figure 5A). The mice
appeared healthy during the entire time period, fed well and were
active. Serum levels of TNF-a, and IL-10 and spleen weights at
killed were similar between the three groups indicating that ODNs
did not induce inflammatory cytokines (data not shown).
Harvested tumours were evaluated by H/E (Figure 5B, upper
panel), which shows large areas of tumour necrosis in AS-10-
treated tumours. Immunohistochemical evaluation with Ki-67
staining shows a 10-fold reduction in proliferative cells (Figure 5B,
second panel) and a 12-fold increase in TUNEL-positive cells
(Figure 5B, third panel) consistent with induction of apoptosis as
noted in vitro. Finally, AS-10 treatment resulted in 75% fewer
tumour microvessels by CD31 immunostaining (Figure 5B, lower
panel). Thus, systemic administration of AS-10 inhibits growth of
Hey tumours in mice, along with inhibition of tumour cell
proliferation, induction of apoptosis, and reduction of tumour
microvasculature.
DISCUSSION
In this study, we have evaluated the expression of EphB4 in
ovarian cancer specimens using highly sensitive and specific
monoclonal antibodies against the extracellular domain of EphB4.
We show that EphB4 is overexpressed in a vast majority of
ovarian cancers, with minimal or no expression in normal ovarian
epithelium. We confirmed EphB4 expression complementarily by
studying staining of sections and Western blotting of frozen
samples. Overexpression of EphB4 correlates with advanced
tumour stage and is associated with poor clinical outcome.
A recent report by Wu et al (2006) has also examined mRNA
and protein levels of EphB2 and EphB4 in a cohort of 115 ovarian
cancer specimens. EphB4 was expressed in 80% of the tumour
tissues. High expression of EphB4 on immunostaining correlated
with poorer survival (P¼0.003) and poorer response to chemo-
therapy (P¼0.036). EphB4 expression may thus be a prognostic
marker for outcome and response to therapy in ovarian
cancer.
We were thus interested in understanding the biological role
played by EphB4 in ovarian cancer. To that end, we studied several
ovarian cancer cells line in vitro. The cell lines tested in this study
replicate faithfully human tumour tissue data. All cancer cell lines
examined showed high levels of EphB4 expression, whereas benign
tumour cell lines showed significantly lower levels of EphB4.
Normal ovarian epithelium expresses little to no EphB4. Thus,
EphB4 expression is restricted to malignant ovarian disease with
increased expression with advanced disease stage. Further, all cell
lines examined express low levels of the ligand EphrinB2. This
raises the possibility that EphB4 expressed on ovarian cells may be
constitutively activated by paracrine or autocrine stimulation.
Further, we found detectable basal levels of EphB4 phosphory-
lation under serum-free conditions in Hey cells, which do not
express EphrinB2 at detectable levels on Western blot. It is thus
possible that high levels of EphB4 is sufficient to result in
constitutive activation of EphB4, analogous to several other
receptor tyrosine kinases.
We have shown previously that overexpression of EphB4 in
tumour cells is tightly regulated by known transforming agents
such as EGFR (Masood et al, 2006) and HER-2/neu (Kumar et al,
2006), and inhibited by tumour suppressors such as p53 (Xia et al,
2006) and PTEN (Xia et al, 2005). Here we show that progesterone,
a known tumour suppressor also regulates EphB4 expression.
A
Lipofectamine
EphB4 siRNA∆
EphB4 siRNA
0 h 6 h 9 h
B Lipofectamine EphB4 siRNA∆ EphB4 siRNA
Figure 4 EphB4 favours tumour cell migration and invasion. (A)
Confluent cultures of Hey cells were scraped with a plastic Pasteur pipette
to produce 3-mm-wide cell-free zone in the monolayer. The ability of the
cells to migrate and close the wound following transfection with 25nM
EphB4-specific (EphB4 siRNA) or mutant siRNA (EphB4 siRNAD) was
assessed over 9h. (B) Invasion of Hey cells into Matrigel-coated inserts was
studied as described in the Materials and Methods section. Cells invading
the underside of the inserts in response to 10mgml
–1 EGF in the lower
chamber were fixed and stained with Giemsa. Representative photo-
micrographs are shown.
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sHoc-7 cells are known to express functional progesterone receptor
and have reduced viability in response to progesterone receptor
agonists. We show for the first time that progesterone down-
regulates EphB4 expression in a dose-dependent fashion.
Downregulation of EphB4 correlates with loss in cell viability.
oestrogen, to the contrary, has no effect on EphB4 levels in Hoc-7
cells.
We then evaluated the role of EphB4 in ovarian tumour biology
by achieving selective downregulation of EphB4 expression with
specific siRNA and antisense ODNs. EphB4 knockdown led to a
profound reduction in tumour cell survival accompanied by the
induction of apoptosis. Following EphB4 knockdown, cells were
unable to enter the G0 phase of the cell cycle and began to
accumulate fragmented nucleosomes in the cytoplasm consistent
with apoptosis. In addition, there was significant induction of
caspase-8 activity, and a much smaller induction of caspase-9
activity, indicating that EphB4 protects tumour cells from the
extrinsic, membrane-originating apoptotic pathways. Several
possible mechanisms may underlie this antiapoptotic effect of
EphB4. We have shown in breast and head and neck cancer cells
that the extracellular domain of EphB4 is capable of protecting
tumour cells from TRAIL-induced apoptosis (Kumar et al, 2006;
Masood et al, 2006). Stimulation of death receptors 4 and 5 by
TRAIL results in selective tumour-cell death, whereas normal cells
have several mechanisms to bypass the proapoptotic effect of
TRAIL. Thus, overexpression of EphB4 by tumour cells may
interrupt TRAIL-mediated apoptosis thus providing survival
advantage to tumour cells. In addition, we have shown that EphB4
upregulates several antiapoptotic proteins, particularly bcl-xl, in
bladder and breast cancer cells (Kumar et al, 2006; Xia et al, 2006),
thus suggesting other sites of action by which EphB4 may inhibit
tumour cell apoptosis.
We suspected that if EphB4 expression could promote
tumour cell viability, it might also promote other features of
malignant carcinomas, such as tumour migration and invasion.
Our human tumour data confirm that increased expression of
EphB4 correlates with the presence of peritoneal disease and
ascites, consistent with extra-ovarian spread of the disease.
In addition, previous studies by Munarini et al (2002) have
shown that overexpression of EphB4 in the breast of mice in the
context of neuT results in highly malignant breast cancers that
metastasise to the lung, a phenomenon that was uniformly
absent in tumours of mice that overexpressed neuT only
(Munarini et al, 2002). Our studies in vitro confirm that EphB4
knockdown leads to a profound inhibition in the ability of tumour
cells to migrate and re-populate a wound or invade through
basement membrane. These effects were observed at early time
points when siRNA had no effect on cell survival. It is likely that
inhibition of migration following knockdown of EphB4 is an early
event and involves downstream pathways that may be different
from those that impact cell survival. Hence, EphB4 affords a
malignant phenotype to ovarian cancer cells by favouring tumour
cell migration and invasion, independent of its direct prosurvival
signals.
EphB4 is critically required for blood vessel maturation in the
foetus (Gerety et al, 1999) and at adult sites of neovascularization
(Shin et al, 2001). In addition, tumour cell-expressed EphB4 can
interact with endothelial EphrinB2 to favour tumour vascularisa-
tion (Noren et al, 2004). Hence, apart from providing direct
survival cues to tumour cells in vitro, EphB4 may also have a
proangiogenic effect in vivo. Therefore, targeting EphB4 may have
a dual benefit in ovarian cancer – abolishing direct tumour cell
antiapoptotic signals and inhibiting tumour vascularisation. We
have tested this hypothesis in a murine model of human ovarian
tumour xenograft. EphB4 knockdown by systemic antisense
administration led to an 85% reduction in tumour volume at 6
weeks. This was accompanied by a reduction in tumour cell
proliferation and increased tumour cell apoptosis. In addition,
EphB4-depleted tumours had a significant reduction in tumour
microvasculature, consistent with an antiangiogenic effect of
EphB4 knockdown in vivo.
EphB4 is highly expressed by a majority of ovarian cancers and
its expression correlates with advanced disease stage, presence of
ascites and decreased survival. Our study shows for the first time
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Figure 5 EphB4-specific antisense ODN inhibits tumour growth in a murine ovarian cancer xenograft model. (A)2 10
6 Hey cells were implanted in the
flank of 10- to 12-week-old female Balb/C athymic mice and tumour volume measured as detailed in the Materials and Methods section. Mice were
administered vehicle alone (vehicle), or 10mgkg
–1scrambled ODN (scrambled) or EphB4-specific antisense ODN (AS-10) intraperitoneally daily starting
day 4 after cell implantation. Animals were killed 5 weeks later and tumours harvested. (B) Sections (5mm) of formalin-fixed paraffin embedded sections
were stained with hematoxylin/eosin and analysed by immunohistochemistry for Ki-67 and CD31 expression. Apoptosis was evaluated by TUNEL with the
in situ apoptosis staining kit. Number of cells staining positive was averaged over five random high-power fields by a blinded observer and indicated in each
micrograph. *Po0.05 between AS-10 and control group. Bar in bottom left panel represents 200mm in H/E, 100mm in CD31, and 75mm in other
photomicrographs.
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sthat the overexpressed receptor favours tumour cell survival
by inhibiting apoptosis, and supports tumour cell migration and
invasion. EphB4 knockdown inhibits murine tumour xenografts by
inducing tumour cell apoptosis and reducing tumour microvascu-
lature. Taken together, these results establish EphB4 as a novel
target for biological therapy in ovarian cancer.
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